Compare BRID & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | ANVS |
|---|---|---|
| Founded | 1932 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.1M | 69.1M |
| IPO Year | 1995 | 2019 |
| Metric | BRID | ANVS |
|---|---|---|
| Price | $6.91 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 4.6K | ★ 1.3M |
| Earning Date | 06-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $174,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $6.57 | $1.54 |
| 52 Week High | $8.73 | $5.50 |
| Indicator | BRID | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 42.81 |
| Support Level | N/A | $1.74 |
| Resistance Level | $8.09 | $2.38 |
| Average True Range (ATR) | 0.29 | 0.13 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 30.74 | 21.43 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.